Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) to Ring The Nasdaq Stock Market Closing Bell

What: 

Corbus Pharmaceuticals Holdings, Inc. (Nasdaq:CRBP), a clinical stage drug development company focused on the development and commercialization of treatments for rare, life-threatening inflammatory and fibrotic diseases, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Yuval Cohen, Ph.D., Chief Executive Officer, will ring the Closing Bell. 

Where:

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Friday, April 17, 2015 – 3:45 p.m. to 4:00 p.m. ET  

Corbus Pharmaceuticals Holdings, Inc. Media Contact:David Schull or Marissa GoberdhanRusso Partners, LLC+1 (858) [e-mail] or [e-mail]  

Nasdaq MarketSite:Christine Barna(646) [e-mail]  

Feed Information:Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West18 mhz LowerDL 3811 VerticalFEC 3/4SR 13.235DR 18.295411MOD 4:2:0DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq 

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaq 

For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/ 

Webcast:

A webcast of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx 

Photos: 

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Corbus Pharmaceuticals Holdings, Inc. (Nasdaq:CRBP):

Corbus Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. The Company’s lead product candidate Resunab™ is a novel oral drug that resolves chronic inflammation and pro-fibrotic processes. Resunab is scheduled to commence Phase 2 clinical trials for the treatment of cystic fibrosis and diffuse cutaneous systemic sclerosis (scleroderma) in 2015. For more information, please visit www.CorbusPharma.com. 

About Nasdaq:

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of approximately $9.5 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-